Patents by Inventor Marian E. Major

Marian E. Major has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified HCV peptide immunogens
    Patent number: 7341726
    Abstract: Provided are an isolated peptide having the amino acid sequence DLMGYIPAV (SEQ ID NO: 1), an isolated HCV core polypeptide comprising an L?A substitution at amino acid position 139, an isolated HCV core polypeptide having the amino acid sequence of SEQ ID NO: 2, and a fragment of an HCV core polypeptide having fewer amino acids than the entire HCV core polypeptide and comprising the amino acid sequence of SEQ ID NO:1. Also provided are nucleic acids which encode the peptides and polypeptides of this invention, vectors comprising the nucleic acids of this invention and cells comprising the vectors and nucleic acids of this invention. Further provided are methods of producing an immune response in a subject and/or treating or preventing HCV infection in a subject, comprising administering to the subject, or to a cell of the subject, any of the compositions of this invention.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: March 11, 2008
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Jay A. Berzofsky, Pablo Sarobe, Stephen M. Feinstone, Marian E. Major
  • Modified HCV peptide vaccines
    Patent number: 7074410
    Abstract: Provided are an isolated peptide having the amino acid sequence DLMGYIPAV (SEQ ID NO: 1), an isolated HCV core polypeptide comprising an L?A substitution at amino acid position 139, an isolated HCV core polypeptide having the amino acid sequence of SEQ ID NO: 2, and a fragment of an HCV core polypeptide having fewer amino acids than the entire HCV core polypeptide and comprising the amino acid sequence of SEQ ID NO:1. Also provided are nucleic acids which encode the peptides and polypeptides of this invention, vectors comprising the nucleic acids of this invention and cells comprising the vectors and nucleic acids of this invention. Further provided are methods of producing an immune response in a subject and/or treating or preventing HCV infection in a subject, comprising administering to the subject, or to a cell of the subject, any of the compositions of this invention.
    Type: Grant
    Filed: February 2, 2004
    Date of Patent: July 11, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jay A. Berzofsky, Stephen M. Feinstone, Marian E. Major, Pablo Sarobe
  • Modified HCV peptide vaccines
    Patent number: 6685944
    Abstract: The present invention provides 1) an isolated peptide having the amino acid sequence DLMGYIPAV, (SEQ ID NO: 1); 2) an isolated HCV core polypeptide comprising an L→A substitution at amino acid position 139; 3) an isolated HCV core polypeptide having the amino acid sequence of SEQ ID NO: 2; and 4) a fragment of an HCV core polypeptide having fewer amino acids than the entire HCV core polypeptide and comprising the amino acid sequence SEQ ID NO: 1. Also provided are nucleic acids which encode the peptides and polypeptides of this invention, vectors comprising the nucleic acids of this invention and cells comprising the vectors and nucleic acids of this invention. The present invention further provides methods of producing an immune response in a subject and/or treating or preventing HCV infection in a subject, comprising administering to the subject, or to a cell of the subject, any of the compositions of this invention.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: February 3, 2004
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jay A. Berzofsky, C. David Pendleton, Stephen M. Feinstone, Marian E. Major, Pablo Sarobe